Caribou Biosciences Q4/FY2024 net loss $149.1M; cash $249.4M into H2 2026; CSO retiring

Caribou Biosciences, Inc.

Net loss $149.1M in 2024 vs $102.1M in 2023; revenue fell to $10.0M from $34.5M on AbbVie deal end.
Cash, equivalents & marketable securities $249.4M at Dec 31, 2024, funding operations into H2 2026.
CB-010 ANTLER and CB-011 CaMMouflage Phase 1 clinical data expected in H1 2025.
CSO Steve Kanner to retire end of June 2025; no replacement planned; functions split among execs.
CFO Sri Ryali appointed in January 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.